What Is the Future of the Tyrosine Hydroxylase Deficiency Drugs Market? Growth Forecasts & Insights Global Tyrosine Hydroxylase Deficiency Drugs market is gaining strategic importance within the rare neurological disorders landscape, supported by advancing diagnostics and heightened clinical awareness. Valued at USD 12.5 million in 2024, the market is projected to grow from USD 13.8 million in 2025 to USD 22.1 million by 2032, registering a CAGR of 6.9% during the forecast period. This sustained growth reflects increasing recognition of Tyrosine Hydroxylase Deficiency (THD) as a treatable condition requiring lifelong, specialized therapeutic management. Access the market report https://www.24lifesciences.com/tyrosine-hydroxylase-deficiency-drugs-market-9215